Selatogrel for Heart Attack
(SOS-AMI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are already on oral triple antithrombotic therapy (a combination of blood-thinning medications).
How does the drug Selatogrel differ from other heart attack treatments?
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Viatris Innovation GmbH
Are You a Good Fit for This Trial?
This trial is for patients who've had a type 1 heart attack within the last 4 weeks and have additional cardiovascular risks like diabetes, kidney disease, or prior heart attacks. They must be able to use an autoinjector and not have severe liver issues, recent strokes, known allergies to P2Y12 drugs like Selatogrel, bleeding risks or be on certain blood thinners.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Randomization and Treatment
Participants are randomized to receive either selatogrel or placebo, and self-administer the study treatment upon experiencing symptoms suggestive of an acute myocardial infarction
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of clinical status and bleeding events
What Are the Treatments Tested in This Trial?
Interventions
- Selatogrel
Find a Clinic Near You
Who Is Running the Clinical Trial?
Viatris Innovation GmbH
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Lead Sponsor
Antonio Olivieri
Idorsia Pharmaceuticals Ltd.
Chief Medical Officer since 2024
Not specified
André C. Muller
Idorsia Pharmaceuticals Ltd.
Chief Executive Officer
Not specified